Foundry Founders Take Stock
This article was originally published in The Gray Sheet
Hanson Gifford III and Mark Deem, two co-founders of the prolific medtech incubator The Foundry, have had a hand in generating more than $2 billion in value for medtech investors and entrepreneurs during the incubator’s 15-plus years. At IN³ Medical Device 360° in Dublin, the pair shared some of the lessons they have learned along the way.
You may also be interested in...
The appointments of three device industry veterans to the Brookings-administered, and partially FDA-funded, Planning Board is intended to expand the range of input in the next phase of development of a new National Medical Device Surveillance System.
With the announcement that Medtronic is going back to the clinical drawing board after the pivotal SYMPLICITY HTN-3 trial of its renal denervation device failed to meet its primary efficacy endpoint, the industry is taking a cautious but still optimistic stance on the highly touted potential treatment for resistant hypertension.
A decade ago, incuabators were seen as the best medicine for what then ailed the medical device industry, most notably a complex regulatory pathway and a difficult venture financing climate. Perhaps not surprisingly, as both the regulatory path and venture financing grew easier in the mid 2000s, incubators began to struggle, victims of their own financing problems. More recently, two huge acquisitions, Abbott's purchase of Evalve and Medtronic's of Ardian, suggest that at least one incubator, The Foundry, is proving that incubation works.